What is NUPLAZID?
NUPLAZID (pimavanserin) is a medication that was approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is the first and only medication approved for this specific use.
NUPLAZID is an atypical antipsychotic that works by selectively blocking serotonin receptors in the brain. Unlike other antipsychotic medications, it does not block dopamine receptors, which are associated with movement disorders such as Parkinson's disease.
NUPLAZID is available in 17mg tablet form and is taken orally once daily with or without food. The dosage may need to be adjusted based on individual response and tolerability.
NUPLAZID has also been studied for use in other conditions, including Alzheimer's disease, schizophrenia, and depression. While it has not been approved for these uses, research is ongoing to evaluate its efficacy for these and other conditions.
As with all medications, NUPLAZID can cause side effects, including nausea, confusion, hallucinations, and abnormal dreams. It is important to discuss any potential side effects with a healthcare provider before starting NUPLAZID, and to report any side effects experienced while taking the medication.
Overall, NUPLAZID represents an important treatment option for individuals with Parkinson's disease psychosis, and ongoing research may lead to additional uses for this medication in the future.
Frequently Asked Questions about nuplazid
In Parkinson's, psychosis may be due to the disease itself or the medications used to treat it. Nuplazid is an atypical antipsychotic medication that works on the serotonin brain chemical system.
Pimavanserin (Nuplazid™) is an atypical antipsychotic currently indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. The antipsychotic effects of this new agent are believed to occur via selective inverse agonist activity at serotonin 5-HT2a receptors.
Each round, white to off-white, immediate- release, film-coated tablet contains 20 mg of pimavanserin tartrate, which is equivalent to 17 mg of Reference ID: 3924821 Page 8 8 pimavanserin free base. Inactive ingredients include pregelatinized starch, magnesium stearate, and microcrystalline cellulose.
Contact us at Acadia Pharmaceuticals Inc. NUPLAZID® (pimavanserin)
NUPLAZID is a prescription medicine used to treat hallucinations (such as seeing, hearing, or experiencing things that others don't) and delusions (such as believing things that are not true) associated with Parkinson's disease psychosis.
SAPS-PD responder analysis
13.7% of NUPLAZID-treated patients experienced complete resolution of symptoms (SAPS-PD score reduced to 0 from baseline) vs 1.1% for placebo.
Pimavanserin was significantly better than placebo in treating delusions and thought disorder. In contrast to antipsychotic medications, the side-effect profile of pimavanserin was similar to that of placebo.
Nuplazid (pimavanserin) is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
The cost for Nuplazid oral capsule 34 mg is around $5,269 for a supply of 30 capsules, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Pimavanserin is a medication used to treat and manage the hallucinations and delusions associated with Parkinson disease psychosis. It is in the atypical antipsychotic class of drugs.
Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Dosage and Administration Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.
NUPLAZID is the only medication approved by the U.S. FDA for the treatment of hallucinations and delusions associated with PDP. “We were encouraged by this large, real-world study showing a lower mortality risk in patients with PDP after initiation of NUPLAZID, compared to other atypical antipsychotics.
What warnings should I know about NUPLAZID? QT Interval Prolongation: NUPLAZID may increase the risk of changes to your heart rhythm. This risk may increase if NUPLAZID is taken with certain other medications known to prolong the QT interval.
NUPLAZID® is an FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis.
Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions).
NUPLAZID® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [see Clinical Studies (14)]. The recommended dose of NUPLAZID is 34 mg taken orally once daily, without titration.
